A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

Trial Identifier: V940-014
Sponsor: Merck
Collaborator:
ModernaTX, Inc.
Start Date: May 2026
Primary Completion Date: August 2034
Study Completion Date: May 2038
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Protocol Plain Language Summary

Trial Locations

Country Location
Australia, Western Australia Nedlands, Western Australia, Australia, 6009
Canada, ON Hamilton, ON, Canada, L8V 5C2
Canada, ON Kingston, ON, Canada, K7L 2V7
Canada, QC Montreal, QC, Canada, H2X 3E4
Netherlands, Gelderland Harderwijk, Gelderland, Netherlands, 3844 DG
Netherlands, Groningen Groningen, Netherlands, 9713 GZ
Netherlands, Utrecht Amersfoort, Utrecht, Netherlands, 3813 TZ
Taiwan, Taichung Taichung, Taiwan, 407
Taiwan, Tainan Tainan, Taiwan, 704
Taiwan, Taipei Taipei, Taiwan, 110
Turkey, Ankara Ankara, Turkey, 6230
United States, MT Billings, MT, United States, 59101
United States, ND Grand Forks, ND, United States, 58201
United States, NE Lincoln, NE, United States, 68506
United States, NV Reno, NV, United States, 89502
United States, NY White Plains, NY, United States, 10601
United States, TN Knoxville, TN, United States, 37920